PI3K and mTOR inhibitors - a new generation of targeted anticancer agents

被引：100

作者：

Brachmann, Saskia ^{[1
]}

Fritsch, Christine ^{[1
]}

Maira, Saveur-Michel ^{[1
]}

Garcia-Echeverria, Carlos ^{[1
]}

机构：

[1] Novartis Inst Biomed Res, Basel, Switzerland

来源：

CURRENT OPINION IN CELL BIOLOGY | 2009年 / 21卷 / 02期

关键词：

PHOSPHATIDYLINOSITOL 3-KINASE/MAMMALIAN TARGET; RAPAMYCIN INHIBITOR; DRUG DISCOVERY; PATHWAY; KINASE; CANCER; ACTIVATION; NVP-BEZ235; ANTITUMOR; GROWTH;

D O I：

10.1016/j.ceb.2008.12.011

中图分类号：

Q2 [细胞生物学];

学科分类号：

071009 ; 090102 ;

摘要：

Epidemiological and experimental studies support an important role of the phosphoinosite 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) pathway in the biology of human cancers. Over the past few years a number of components of this signaling cascade have been the subject of intense drug discovery activities. This article summarizes progress made in the identification of kinase inhibitors of PI3K and mTOR, with an emphasis placed on drugs currently undergoing clinical trials. Potential combination strategies, safety concerns, and resistance mechanisms for this new generation of anticancer agents are also discussed.

引用

收藏

页码：194 / 198

页数：5

相关论文

共 40 条

[31] PI3K enters beta-testing [J].

Shaywitz, Adam J. ;

Courtney, Kevin D. ;

Patnaik, Akash ;

Cantley, Lewis C. .

CELL METABOLISM, 2008, 8 (03) :179-181

[32] The BAD protein integrates survival signaling by EGFR/MAPK and PI3K/Akt kinase pathways in PTEN-deficient tumor cells [J].

She, QB ;

Solit, DB ;

Ye, Q ;

O'Reilly, KE ;

Lobo, J ;

Rosen, N .

CANCER CELL, 2005, 8 (04) :287-297

[33]

STRIMPAKOS AS, 2009, CANC TREAT IN PRESS

[34]

Walker EH, 2000, MOL CELL, V6, P909, DOI 10.1016/S1097-2765(00)00088-5

[35] Structural insights into phosphoinositide 3-kinase catalysis and signalling [J].

Walker, EH ;

Perisic, O ;

Ried, C ;

Stephens, L ;

Williams, RL .

NATURE, 1999, 402 (6759) :313-320

[36] PTEN-deficient cancers depend on PIK3CB [J].

Wee, Susan ;

Wiederschain, Dmitri ;

Maira, Sauveur-Michel ;

Loo, Alice ;

Miller, Christine ;

DeBeaumont, Rosalie ;

Stegmeier, Frank ;

Yao, Yung-Mae ;

Lengauer, Christoph .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2008, 105 (35) :13057-13062

[37] Targeting the PI3K-AKT-mTOR pathway: progress, pitfalls, and promises [J].

Yap, Timothy A. ;

Garrett, Michelle D. ;

Walton, Mike I. ;

Raynaud, Florence ;

de Bono, Johann S. ;

Workman, Paul .

CURRENT OPINION IN PHARMACOLOGY, 2008, 8 (04) :393-412

[38] Raptor, a binding partner of target of rapamycin [J].

Yonezawa, K ;

Tokunaga, C ;

Oshiro, N ;

Yoshino, K .

BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2004, 313 (02) :437-441

[39] Class 1A PI3K regulates vessel integrity during development and tumorigenesis [J].

Yuan, Tina L. ;

Choi, Hak Soo ;

Matsui, Aya ;

Benes, Cyril ;

Lifshits, Eugene ;

Luo, Ji ;

Frangioni, John V. ;

Cantley, Lewis C. .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2008, 105 (28) :9739-9744

[40]

Zunder E. R., 2008, CANCER CELL, V14, P107

← 1 2 3 4 →